BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
HIV clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for HIV: 85 (30 sponsors; 18 newly posted in the last 180 days, 3 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 20.6, rank 28 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 19, Phase 2 30, Phase 3 23, Phase 4 3, N/A 8.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| ViiV Healthcare | 27 | P2 6, P1 12, P3 9 | 7 | 5 |
| Merck Sharp & Dohme LLC MRK | 11 | P2 4, P3 6, P1 1 | 3 | 1 |
| Gilead Sciences GILD | 14 | P1 2, P2 4, P3 5, P4 2, NA 1 | 3 | 0 |
| Jiangsu Aidea Pharmaceutical Group Co., Ltd. new entrant | 2 | P2 1, P3 1 | 2 | 0 |
| Biofabri, S.L | 1 | P3 1 | 0 | 0 |
| Serum Institute of India Pvt. Ltd. | 1 | P3 1 | 0 | 1 |
| BioNTech SE BNTX | 3 | P1 2, P2 1 | 1 | 0 |
| bioLytical Laboratories | 2 | NA 2 | 0 | 2 |
| Frantz Viral Therapeutics, LLC | 2 | P2 2 | 0 | 2 |
| Jecho Biopharmaceuticals Co., Ltd. | 2 | P1 1, P2 1 | 0 | 1 |
| American Gene Technologies International Inc. AIG | 1 | NA 1 | 0 | 0 |
| American Laboratory Products Company AIG | 1 | NA 1 | 0 | 1 |
| Calimmune, Inc. | 1 | NA 1 | 0 | 0 |
| Cell Energy Life Sciences Group Co. LTD | 1 | P2 1 | 0 | 0 |
| Code Pharma | 1 | P2 1 | 0 | 0 |
| Epividian | 1 | NA 1 | 0 | 0 |
| Estrella Immunopharma, Inc. ESLA | 1 | P2 1 | 0 | 0 |
| GlaxoSmithKline | 1 | P2 1 | 0 | 1 |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 1 | EARLY_P1 1 | 0 | 0 |
| Henan Genuine Biotech Co., Ltd. | 1 | P2 1 | 0 | 1 |
| Immuno Cure Holding (HK) Limited | 1 | P1 1 | 0 | 1 |
| Liaoning Chengda Biotechnology CO., LTD new entrant | 1 | P4 1 | 1 | 0 |
| MagIA Diagnostics | 1 | NA 1 | 0 | 0 |
| MGB Pharma | 1 | P2 1 | 0 | 0 |
| Mundipharma Research Limited | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Jiangsu Aidea Pharmaceutical Group Co., Ltd., Liaoning Chengda Biotechnology CO., LTD.
Recently stopped trials
- NCT06032546 AbbVie - terminated: Company Decision A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participa
- NCT06652958 ViiV Healthcare - terminated: Terminated for business reasons A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Perso
- NCT06082336 MagIA Diagnostics - terminated: Liquidation of MagIA Diagnostics Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screEN
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | UBP Greater China (Shanghai) Co., Ltd | NCT04985890 A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir | HIV-1-infection | not yet recruiting | 20 |
| 2026-12 est. | P2 | Henan Genuine Biotech Co., Ltd. | NCT07308782 A Phase Ⅱa Clinical Study of CL-197 Capsules | HIV-1 Infection | recruiting | 24 |
| 2027-02-12 est. | P1/P2 | Jecho Biopharmaceuticals Co., Ltd. | NCT07579741 A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | HIV Infections | recruiting | 30 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-03 | P2/P3 | Gilead Sciences GILD | NCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Su | HIV-1-Infection | terminated | 80 |
| 2026-09-09 | P2 | ViiV Healthcare | NCT06741397 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Do | HIV Infections | active not recruiting | 229 |
| 2026-08-19 | P3 | ViiV Healthcare | NCT06694805 A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 | HIV Infections | active not recruiting | 326 |
| 2026-08-18 | P2 | Janssen Sciences Ireland UC | NCT02494986 A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies | Human Immunodeficiency Virus Type 1 | completed | 48 |
| 2026-07-27 | P2 | Gilead Sciences GILD | NCT06101342 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 181 |
| 2026-07-22 | P2 | Gilead Sciences GILD | NCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 253 |
| 2026-07-10 est. | P1/P2 | Shanxi Kangbao Biological Product Co., Ltd. | NCT07433387 Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals | HIV | recruiting | 30 |
| 2026-06-30 est. | P3 | United BioPharma UTHR | NCT04406727 UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | HIV-1 Infection | unknown | 50 |
| 2026-06-01 est. | P1/P2 | ViiV Healthcare | NCT05674656 Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics | HIV Infections | recruiting | 20 |
| 2026-05-28 | P2 | Gilead Sciences GILD | NCT06513312 Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 268 |
| 2026-05-27 | P2 | ViiV Healthcare | NCT05996471 A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Hu | HIV Infections | active not recruiting | 185 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "HIV"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.